eli lilly glp 1 mounjaro endowment gets nod to launch weight-loss drug in Hong Kong - Bloomberg News Eli Lilly to seek approval

While some ingredients show limited potential, the evidence remains nuanced and should be interpreted carefully

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

Study finds GLP-1 receptor agonists do not increase pancreatitis risk and are associated with fewer complications in Type 2 diabetes.

While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron

Rapid weight loss with GLP1 receptor agonists can come at the cost of skeletal muscle, potentially undermining metabolic and functional outcomes